drugset / Trial / NCT02106130

A Drug Interaction Study of Mosapride and Rebamipide

NCT02106130

Phase 1 Completed 40 enrolled IlDong Pharmaceutical Co Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

The investigators investigate the potential pharmacokinetic drug-drug interaction between Mosapride citrate 5 mg and Rebamipide 100 mg in healthy male volunteers who receive Mosapride citrate 5 mg, Rebamipide 100 mg, and both together in a 2 period repeatedly.

Timeline

Start
2013-05
Primary completion
2013-06
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Mosapride Small molecule 5 mg Oral
Subject Rebamipide Small molecule 100 mg Oral

Indications

No indication recorded.